*Genetic Association Studies *Genetic Predisposition to Disease Genotype Glutathione Transferase/*genetics Humans Odds Ratio *Polymorphism Genetic Publication Bias Risk Urinary Bladder Neoplasms/*genetics Bladder cancer Gstm1 Gstp1 Gstt1 Gene polymorphism Meta-analysis PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

长链非编码RNA 膀胱癌 预后 Meta分析

*Cost-Benefit Analysis Cystectomy/*economics/*methods Humans *Laparoscopy *Robotic Surgical Procedures Urinary Bladder Neoplasms/*economics/*surgery

Female Humans Male Prospective Studies *Quality of Life Urinary Bladder Neoplasms/drug therapy/*psychology/radiotherapy Bladder cancer Chemotherapy Muscle-invasive bladder cancer Quality of life Urothelial cancer PUBLICATION: Not applicable. COMPETING INTERESTS: The authors declare that they have no competing interests. PUBLISHER’S NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Biopsy/methods Carcinoma in Situ/*pathology/*therapy Humans Muscle Smooth Neoplasm Invasiveness Urinary Bladder Neoplasms/*pathology/therapy Biopsias aleatorias de vejiga Carcinoma in situ Non-muscle invasive bladder cancer Random bladder biopsies Tumor vesical no-músculo invasivo

Bacille Calmette-Guérin Nmibc gemcitabine intravesical therapy meta-analysis non-muscle invasive bladder cancer

Bladder cancer Pd-1 Pd-l1 atezolizumab avelumab biomarkers durvalumab immunotherapy nivolumab pembrolizumab Urogen licenses/patents: University of Colorado research support: Medivation/Astellas stockholder in: Aurora Oncology PrecisionProfile other: IOS Press (editorial responsibilities compensated).The other authors report no conflicts of interest.

bladder tumor childhood exposure environmental smoking nonsmoking adult

Cystectomy/*methods Humans *Robotic Surgical Procedures Treatment Outcome Urinary Bladder Neoplasms/*surgery Oncologic outcome Open radical cystectomy Positive surgical margin Robot-assisted radical cystectomy

Diabetes Mellitus Type 2/complications/drug therapy Humans Hypoglycemic Agents/*adverse effects/therapeutic use Odds Ratio Pioglitazone/*adverse effects/therapeutic use Randomized Controlled Trials as Topic Risk Assessment Risk Factors Time Factors Urinary Bladder Neoplasms/*etiology Bladder cancer dose-response relationship meta-analysis pioglitazone

Cystectomy Humans Procedures and Techniques Utilization/*statistics & numerical data Prospective Studies Retrospective Studies Risk Assessment Urinary Bladder Neoplasms/*surgery Predictors Radical cystectomy Use Utilization interest including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg employment/affiliation grants or funding consultancies honoraria stock ownership or options expert testimony royalties or patents filed received or pending) are the following: None.

Blood Loss Surgical *Cystectomy Diet Humans Lymph Nodes/pathology *Minimally Invasive Surgical Procedures Postoperative Complications/etiology Randomized Controlled Trials as Topic Recurrence Treatment Outcome Urinary Bladder Neoplasms/*surgery Open radical cystectomy laparoscopic radical cystectomy meta-analysis minimally invasive randomized controlled trials robot-assisted radical cystectomy

经尿道膀胱肿瘤电切术 经尿道前列腺电切术 同期手术 Meta分析 TURBT TURP

YBC® rapid test bladder cancer diagnostic meta-analysis

Cystectomy/*adverse effects Humans Lymphatic Metastasis Neoplasm Invasiveness Neoplasm Recurrence Local/etiology/*pathology Urinary Bladder Neoplasms/pathology/*surgery Vascular Neoplasms/etiology/*pathology Bladder cancer Lymph node dissection Lymphovascular invasion Meta-analysis Metastasis Radical cystectomy

吡格列酮 糖尿病人群 系统回顾

Antineoplastic Combined Chemotherapy Protocols/*therapeutic use Cisplatin/administration & dosage Deoxycytidine/administration & dosage/analogs & derivatives Doxorubicin/administration & dosage Humans Methotrexate/administration & dosage Muscle Neoplasms/*drug therapy/pathology Neoplasm Invasiveness Prognosis Survival Rate Urinary Bladder Neoplasms/*drug therapy/pathology Vinblastine/administration & dosage Gemcitabine Bladder cancer and cisplatin chemotherapy doxorubicin/adriamycin gemcitabine and cisplatin methotrexate vinblastine

前列腺癌 放疗 继发性膀胱癌 前列腺癌根治术

Combined Modality Therapy *Cystectomy Disease-Free Survival Humans Muscles/*pathology Neoplasm Invasiveness Publication Bias Urinary Bladder Neoplasms/*pathology/*therapy

bladder cancer clinicopathological characteristics lncRNA prognosis